



# Publications du GPCO



**[Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care](#)** (Br J Cancer, 2024)

*Blanchet B, Xu-Vuillard A, Jouinot A, Puisset F, Combarel D, Huillard O, LeLouedec F, Thomas F, Teixeira M, Flippot R, Mourey L, Albiges L, Pudlarz T, Joly C, Tournigand C, Chauvin J, Puszkiel A, Chatelut E, Decleves X, Vidal M, Goldwasser F, Oudard S, Medioni J, Vano YA*

**[Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing](#)** (Clin Chem Lab Med, 2024)

*Loison G, Bouges Le Royer H, Marsili S, Brice A, Vintejou J, Yakoubi M, Sirgue H, Chatelut E, Etienne-Grimaldi MC, Thomas F*

**[Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency](#)** (European journal of cancer, 2023)

*Marie-Christine Etienne-Grimaldi, Nicolas Pallet, Valérie Boige, Joseph Ciccolini, Laurent Chouchana, Chantal Barin-Le Guellec, Aziz Zaanani, Céline Narjoz, Julien Taieb, Fabienne Thomas, and Marie-Anne Lorient.*

**[Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters !](#)** (Clinical Pharmacology & Therapeutics, 2022)

*Fabienne Thomas, Manon Launay, Jérôme Guillon, Marie-Anne Lorient, Jean-Christophe Boyer, Vincent Haufroid, Marie-Christine Etienne-Grimaldi, and Bernard Royer.*

**[Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency](#)** (BJCP, 2022)

*Maud Maillard, Manon Launay, Bernard Royer, Jérôme Guillon, Elodie Gautier-Veyret, Sophie Broutin, Camille Tron, Félicien Le Louedec, Joseph Ciccolini, Damien Richard, Hugo Alarcán, Vincent Haufroid, Naïma Tafzi, Antonin Schmitt, Marie-Christine Etienne-Grimaldi, Céline Narjoz, and Fabienne Thomas.*

**[Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study](#)**

(Pharmaceuticals, 2021) *Clémence Marin, Nihel Khoudour, Aurélien Millet, Dorothée Lebert, Pauline Bros, Fabienne Thomas, David Ternant, Bruno Lacarelle, Jérôme Guillon, Joseph Ciccolini, and Benoit Blanchet.*

**[Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation](#)** (Annals of oncology, 2021)

*Fabienne Thomas, Maud Maillard, Manon Launay, Camille Tron, Marie-Christine Etienne-Grimaldi, Elodie Gautier-Veyret, Vincent Haufroid, Nicolas Pallet, Bernard Royer, Céline Narjoz, and Antonin Schmitt.*

[Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients](#) (Cancer Chemother Pharmacol, 2021)

*Lunar N, Etienne-Grimaldi MC, Macaire P, Thomas F, Dalenc F, Ferrero JM, Pivot X, Milano G, Royer B, Schmitt A*

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists](#) (Bull Cancer, 2019)

*Loriot MA, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delalogue S, Malka D, Guigay J, Thariat J, Thomas F, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC*

[Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib](#) (Clin pharmacokinet, 2019)

*Puszekiel A, Noé G, Bellesoeur A, Kramkimmel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B.*

[A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO UNICANCER proof of concept study in head-and-neck cancer patients](#) (Scientific Reports, 2017)

*François Becher, Joseph Ciccolini, Diane-Charlotte Imbs, Clémence Marin, Claire Fournel, Charlotte Dupuis, Nicolas Fakhry, Bertrand Pourroy, Aurélie Ghetas, Alain Pruvost, Christophe Junot, Florence Duffaud, Bruno Lacarelle, and Sebastien Salas.*

[Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing](#) (Seminars in Oncology, 2017)

*Marie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, Etienne Chatelut, Alexandre Evrard, Marie-Anne Loriot, Angelo Paci, Bernard Royer, Fabienne Thomas, and Joseph Ciccolini.*

[Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients.](#) (Pharm Biomed Anal, 2017)

*Puszekiel A, Noé G, Boudou-Rouquette P, Cossec CL, Arrondeau J, Giraud JS, Thomas-Schoemann A, Alexandre J, Vidal M, Goldwasser F, Blanchet B.J*